Latest:
Bone-Targeted Therapies Evolve in Prostate Cancer
The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Devin C. Flaherty, DO, PhD
Latest:
Interdisciplinary Tumor Conferences: A Surgical Oncology Fellow's Review and Perspective
Devin C. Flaherty, DO, PhD, a surgical oncology fellow, discusses the evolution of interdisciplinary tumor board conferences and remarks on why they are so beneficial to the care of patients with cancer.
Dian Wang, MD
Latest:
Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma
As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.
Diana Osorio, MD
Latest:
Providing Oncology Services in Impoverished Countries
Many of us training in the United States have encountered patients and their families from resource-limited regions of the world-families who have uprooted themselves for the chance to save the lives of their children diagnosed with cancer.
Diana Verrilli, MS
Latest:
Moving to Electronic Prior Authorization Requires Incremental Steps
In a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1
Diane Corjulo, BSN
Latest:
Merging Community Practices With an Academic Cancer Center
Consolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Diane Simeone, MD
Latest:
Dr. Simone Discusses the Precision Promise Trial in Pancreatic Cancer
Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.